BNP PARIBAS ARBITRAGE/CALL/ELI LILLY & CO/900/0.01/20.09.24 | Real-time Borsa Italiana 03:08:29 2024-06-03 am EDT | ||
| 0.334 EUR | +12.46% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 0.334 | +12.46% |
| 24-05-31 | 0.297 | +4.21% |
| 24-05-30 | 0.285 | +4.01% |
| 24-05-29 | 0.274 | +5.79% |
| 24-05-28 | 0.259 | -14.24% |
Real-time Borsa Italiana
Last update June 03, 2024 at 03:08 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P22T15 | |
| ISIN | NLBNPIT22T15 |
| Date issued | 2024-05-08 |
| Strike | 900 $ |
| Maturity | 2024-09-20 (110 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.353 € |
|---|---|
| Lowest since issue | 0.1335 € |
| Spread | 0.147 € |
| Spread % | 35.94% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- P22T15 Warrant
